Published October 1, 2009 | Version v1
Journal article

Systems Biology Modeling of the Radiation Sensitivity Network: A Biomarker Discovery Platform

  • 1. Division of Biomedical Informatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (United States)
  • 2. Division of Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (United States)
  • 3. Division of Biostatatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (United States)
  • 4. Division of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (United States)

Description

Purpose: The discovery of effective biomarkers is a fundamental goal of molecular medicine. Developing a systems-biology understanding of radiosensitivity can enhance our ability of identifying radiation-specific biomarkers. Methods and Materials: Radiosensitivity, as represented by the survival fraction at 2 Gy was modeled in 48 human cancer cell lines. We applied a linear regression algorithm that integrates gene expression with biological variables, including ras status (mut/wt), tissue of origin and p53 status (mut/wt). Results: The biomarker discovery platform is a network representation of the top 500 genes identified by linear regression analysis. This network was reduced to a 10-hub network that includes c-Jun, HDAC1, RELA (p65 subunit of NFKB), PKC-beta, SUMO-1, c-Abl, STAT1, AR, CDK1, and IRF1. Nine targets associated with radiosensitization drugs are linked to the network, demonstrating clinical relevance. Furthermore, the model identified four significant radiosensitivity clusters of terms and genes. Ras was a dominant variable in the analysis, as was the tissue of origin, and their interaction with gene expression but not p53. Overrepresented biological pathways differed between clusters but included DNA repair, cell cycle, apoptosis, and metabolism. The c-Jun network hub was validated using a knockdown approach in 8 human cell lines representing lung, colon, and breast cancers. Conclusion: We have developed a novel radiation-biomarker discovery platform using a systems biology modeling approach. We believe this platform will play a central role in the integration of biology into clinical radiation oncology practice.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2009.05.056

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2009.05.056;
PII
S0360-3016(09)00830-X;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
75
Journal Issue
2
Journal Page Range
p. 497-505
ISSN
0360-3016
CODEN
IOBPD3

Optional Information

Copyright
Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.